BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.

ABSTRACT:

Background

Data on the safety and efficacy of SARS-CoV-2 vaccines in immunocompromised populations are sparse.

Methods

We conducted a prospective study of 77 heart transplant (HT) recipients vaccinated with two doses of BNT162b2 vaccine and monitored for adverse events following both doses, the receptor-binding domain (RBD) IgG response, and neutralizing antibodies.

Results

BNT162b2 vaccination was associated with a low rate of adverse events, characterized mostly by pain at the injection site. By a mean 41 days post second dose there were no clinical episodes of rejection, as suggested by a troponin leak or allograft dysfunction. At a mean 21 days following the second dose, IgG anti-RBD antibodies were detectable in 14 (18%) HT recipients. Immune sera neutralized SAR

SUBMITTER: Peled Y 

PROVIDER: S-EPMC8058049 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature